Feb 6 (Reuters) - Coya Therapeutics Inc COYA.O:
COYA THERAPEUTICS INC - REPORTS SIGNIFICANT IMPROVEMENT IN INFLAMMATORY MARKERS IN ALZHEIMER'S PATIENTS
COYA THERAPEUTICS INC - MONTHLY LD IL-2 SHOWS SIGNIFICANT REDUCTION IN CCL2 AND IL-15, INCREASE IN IL-4
COYA THERAPEUTICS INC - LD IL-2 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED
Source text: ID:nBwbTXTkza
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.